Evidence map›Paper›PMID 37259244›Full record

ArticleClinical endoscopy2023

Pancreatic duct lavage cytology combined with a cell-block method for patients with possible pancreatic ductal adenocarcinomas, including pancreatic carcinoma in situ.

Hiroaki Kusunose, Shinsuke Koshita, Yoshihide Kanno, Takahisa Ogawa, Toshitaka Sakai, Keisuke Yonamine, Kazuaki Miyamoto, Fumisato Kozakai, Hideyuki Anan, Kazuki Endo and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endoscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Hiroaki KusunoseDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Shinsuke KoshitaDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Yoshihide KannoDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Takahisa OgawaDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Toshitaka SakaiDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Keisuke YonamineDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Kazuaki MiyamotoDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Fumisato KozakaiDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Hideyuki AnanDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Kazuki EndoDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Haruka OkanoDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Masaya OikawaDepartment of Surgery, Sendai City Medical Center, Sendai, Japan.
Takashi TsuchiyaDepartment of Surgery, Sendai City Medical Center, Sendai, Japan.
Takashi SawaiDepartment of Pathology, Sendai City Medical Center, Sendai, Japan.
Yutaka NodaDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Kei ItoDepartment of Gastroenterology, Sendai City Medical Center, Sendai, Japan.
Sendai Medical Center · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThis study aimed to clarify the efficacy and safety of pancreatic duct lavage cytology combined with a cell-block method (PLC-CB) for possible pancreatic ductal adenocarcinomas (PDACs).

methodsThis study included 41 patients with suspected PDACs who underwent PLC-CB mainly because they were unfit for undergoing endoscopic ultrasonography-guided fine needle aspiration. A 6-Fr double lumen catheter was mainly used to perform PLC-CB. Final diagnoses were obtained from the findings of resected specimens or clinical outcomes during surveillance after PLC-CB.

resultsHistocytological evaluations using PLC-CB were performed in 87.8% (36/41) of the patients. For 31 of the 36 patients, final diagnoses (invasive PDAC, 12; pancreatic carcinoma in situ, 5; benignancy, 14) were made, and the remaining five patients were excluded due to lack of surveillance periods after PLC-CB. For 31 patients, the sensitivity, specificity, and accuracy of PLC-CB for detecting malignancy were 94.1%, 100%, and 96.8%, respectively. In addition, they were 87.5%, 100%, and 94.1%, respectively, in 17 patients without pancreatic masses detectable using endoscopic ultrasonography. Four patients developed postprocedural pancreatitis, which improved with conservative therapy.

conclusionPLC-CB has an excellent ability to detect malignancies in patients with possible PDACs, including pancreatic carcinoma in situ.

Indexed as

Carcinoma in situCell biologyEndoscopic retrograde cholangiopancreatographyPancreatic juicePancreatic neoplasms

Identifiers

PMID37259244
PMCPMC10244143
OpenAlexW4309351256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.